Share this article
Share this article
CAMBRIDGE, Mass., Jan. 26, 2021 /PRNewswire/ Senda Biosciences, a therapeutics platform company creating novel categories of medicines based on a new field of science called Intersystems Biology, announced today that it has entered into a strategic collaboration with Nestlé Health Science for the development of novel nutritional therapies for a wide range of metabolic conditions, including obesity and glycemia.
The companies will focus initially on accelerating first-in-human clinical studies on up to three small molecule compounds developed by Senda, leveraging the capabilities of Nestlé Health Science, a global leader in the science of nutrition. The compounds have been rationally designed based on Senda s Intersystems Biology discovery platform, and screened through Senda s proprietary bioassays for their potential to improve metabolic health. In preclinical studies these compounds have shown the ability to achieve sustained reducti